Phosphodiesterase isozyme 4 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-15Phosphodiesterase isozyme 4 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q86V67. Start with chronic obstructive pulmonary disease, then reuse UniProt Q86V67 as the stable protein anchor across project notes and exports.
Start with chronic obstructive pulmonary disease, then reuse UniProt Q86V67 as the stable protein anchor across project notes and exports.
Phosphodiesterase isozyme 4 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug remains visible in the same block.
Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include UK-500001. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPhosphodiesterase isozyme 4
Review this target as Phosphodiesterase isozyme 4, mapped to UniProt Q86V67. Sequence length is 102 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphodiesterase isozyme 4 as ChEMBL target CHEMBL4523374, mapped to UniProt Q86V67. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Phosphodiesterase isozyme 4 is the right protein anchor across sources, using UniProt Q86V67 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic obstructive pulmonary disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Phosphodiesterase isozyme 4 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q86V67 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Phosphodiesterase isozyme 4 |
| UniProt Accession | Q86V67 |
| Component Type | Protein |
| Sequence Length | 102 aa |
Phosphodiesterase isozyme 4
Review this target as Phosphodiesterase isozyme 4, mapped to UniProt Q86V67. Sequence length is 102 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Phosphodiesterase isozyme 4 shows clinical signal disease relevance led by chronic obstructive pulmonary disease.
Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include UK-500001. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4758412 | 9.05 | IC50 | 0.9 | Preclinical |
| CHEMBL3989967 | 8.55 | IC50 | 2.8 | Clinical |
| CHEMBL4778157 | 7.58 | IC50 | 26.0 | Preclinical |
| CHEMBL3654384 | 5.83 | IC50 | 1479.0 | Clinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 2 | 5 | 7.8 |